Clinical Studies May Be Needed For Cosmetics With Nanomaterials – FDA
This article was originally published in The Rose Sheet
Executive Summary
Due to nanomaterials’ size and the unique behavior they often exhibit, standard tests – and particularly in vitro tests – for assessing product safety may not be appropriate for use, FDA says in new guidance to the cosmetics industry. The agency encourages firms to consult with its cosmetics office prior to launching nanotech-containing products to market.
You may also be interested in...
Existing Safety Principles Suffice For Nano-Cosmetics Evaluation – FDA
FDA maintains that the current framework for cosmetic safety assessment is sufficient to control potential risks associated with nano-engineered cosmetics. However, traditional testing methods may need to be modified or new strategies developed to account for nanomaterials’ unique properties and behavior, the agency says in final guidance issued June 24.
Nanomaterials In Cosmetics May Require Special Testing – ICCR Report
A joint working group convened under the International Cooperation on Cosmetics Regulation determines that toxicological testing and risk-characterization methods for conventional ingredients are sufficient for assessing the safety of nanomaterials. However, the unique properties and behavior of nanomaterials call for modifications to existing strategies and focused evaluation of particles on the nano scale to ensure regulatory compliance and consumer welfare.
FDA To Issue Guidance On Nano Cosmetics, Lead In Lipstick
FDA’s Center for Food Safety and Applied Nutrition intends to issue final guidance on nanomaterial use in cosmetics and draft guidance regarding trace material lead in lipstick during the remainder of 2013 and 2014. Under its regulatory priorities announced Sept. 5, CFSAN’s says the guidances will be part of effort to protect the public from adulterated food and cosmetics.